Cytokinetics CEO Robert I. Blum sells 7,500 shares

The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust each held 2,083 common shares; Blum disclaims beneficial ownership.

Available on EDGAR 11/02/2026 - 06:18 PM EST Accepted by SEC EDGAR 11/02/2026 - 06:18 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Cytokinetics Inc. (CYTK) President & CEO Robert I. Blum exercised options for 7,500 common shares at a $10.60 exercise price and sold 7,500 shares at $62.81 per share on November 2, 2026. The transactions were reported under a Rule 10b5-1 plan. His reported post-exercise balance was 134,245 shares underlying non-qualified stock options.

Insider Trade Summary 10b5-1

Exercise and Sale: 7,500 shares ($392K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Blum Robert I

Role President & CEO

Sold 7,500 shs ($471K)

Approx. gross sale proceeds $471K

Approx. exercise cost $80K

Approx. pre-tax spread $392K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	7,500	$0.00	$0.00
Exercise	Common Stock	7,500	$10.60	$80K
Sale	Common Stock	7,500	$62.81	$471K
Holding	Common Stock F1	--	--	--
Holding	Common Stock F2	--	--	--
Holding	Common Stock	--	--	--

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 134,245 contracts (Direct); Common Stock — 278,544 shares (Direct); Common Stock — 2,083 shares (Indirect, by Trust 1. Beneficial Ownership disclaimed.); Common Stock — 2,083 shares (Indirect, by Trust 2. Beneficial Ownership Disclaimed.); Common Stock — 0 shares (Indirect, by Trust 3. Beneficial Ownership Disclaimed.)

Footnotes (2)

1. F1. Shares held by The Bridget Blum 2003 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the Shares.
2. F2. Shares held by The Brittany Blum 2003 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the Shares.

Key Figures

Shares acquired through option exercise: 7,500 shares Exercise price: $10.60 per share Shares sold: 7,500 shares +4 more

7 metrics

Shares acquired through option exercise 7,500 shares November 2, 2026

Exercise price $10.60 per share November 2, 2026

Shares sold 7,500 shares November 2, 2026

Sale price $62.81 per share November 2, 2026

Shares underlying non-qualified stock options after exercise 134,245 shares Reported post-exercise position

Common shares held by The Bridget Blum 2003 Irrevocable Trust 2,083 shares Blum is a co-trustee and disclaims beneficial ownership

Common shares held by The Brittany Blum 2003 Irrevocable Trust 2,083 shares Blum is a co-trustee and disclaims beneficial ownership

Key Terms

Non-Qualified Stock Option (Right to Buy), Rule 10b5-1 plan, Beneficial Ownership

3 terms

Non-Qualified Stock Option (Right to Buy) financial

"Non-Qualified Stock Option (Right to Buy)"

Rule 10b5-1 plan regulatory

"transactions were reported under a Rule 10b5-1 plan"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

Beneficial Ownership financial

"disclaims any beneficial ownership interest in the Shares"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many CYTK shares did Robert I. Blum sell, and at what price?

Robert I. Blum sold 7,500 CYTK shares at $62.81 per share on November 2, 2026. He exercised options for 7,500 common shares at $10.60 per share, and the transactions were reported under a Rule 10b5-1 plan.

How many shares underlying CYTK options remained after the exercise?

The reported post-exercise balance was 134,245 shares underlying non-qualified stock options.

What CYTK shares were listed under trusts associated with Robert I. Blum?

The Bridget Blum 2003 Irrevocable Trust and The Brittany Blum 2003 Irrevocable Trust each held 2,083 common shares. Blum is a co-trustee of both trusts and disclaims beneficial ownership of the shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blum Robert I

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/02/2026		M		7,500	A	$10.6	286,044	D
Common Stock	11/02/2026		S		7,500	D	$62.81	278,544	D
Common Stock								2,083	I	by Trust 1. Beneficial Ownership disclaimed.(1)
Common Stock								2,083	I	by Trust 2. Beneficial Ownership Disclaimed.(2)
Common Stock								0	I	by Trust 3. Beneficial Ownership Disclaimed.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$10.6	11/02/2026		M			7,500	03/28/2017	02/28/2027	Common Stock	7,500	$0	134,245	D

Explanation of Responses:

1. Shares held by The Bridget Blum 2003 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the Shares.

2. Shares held by The Brittany Blum 2003 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the Shares.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Blum	11/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)